Addressing Bioavailability

Less than 1 min

Addressing Ongoing and New Bioavailability Changes

In this article with OnDrug Delivery Stephanie Emory, Associate Director of Pharmaceutical Development at Metrics Contract Services and former FDA reviewer, discusses the pros and cons of the technological solutions used to address the two main culprits of low solubility: high crystalline lattice energy and greater lipophilicity.

“With so many options for bioavailability enhancement currently available, developers who invest in thorough API characterization are well-poised to swiftly overcome these challenges by identifying the technologies best suited to their product.”

Read the full article here: